COVID-19 Is Positive and Negative for Digital Pathology

Our latest report finds that digital pathology market is 710 million in 2020. The COVID-19 pandemic, while disrupting healthcare in general, also provides a selling point as many pathologists are now at home and need to work digitally. Kalorama Information’s recent study Digital Pathology Markets, 2020-2025, finds a vibrant market that is pushed by the […]

COVID-19 Has Small Negative Impact on Important Companion Diagnostic Testing, Report Finds

Companion diagnostics are rising to the forefront of pharmaceutical development and treatment. Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. The COVID-19 pandemic has gripped the world and continues to be a major area of research and development […]

Cell Therapy Market Reaches 3.8 BN; Cancer Treatments Dominate and COVID-19 Applications Explored

Cell therapy involves the modification of human cell which are used to replace or repair damaged tissues or cells. Two areas with growing development and commercialization include chimeric antigen receptor (CAR)-T therapies and stem cell therapies. According to a recent report from Kalorama Information, the global market for cell and gene therapy in 2020 is […]

Qiagen Adds to Leading Molecular Cancer Menu with FDA-Cleared JAK2 Test Kit

Prognostic and Other Evaluative Tests Kits Join Companion Diagnostics in U.S. Cancer Diagnostics.  Kalorama Information covers molecular in vitro diagnostics (IVD) markets for cancer and blood disorders inThe World Molecular Diagnostics Market, 7th Ed. The U.S. Food and Drug Administration (FDA) recently cleared Qiagen’s ipsogen JAK2 RGQ PCR Kit for detection of the V617F mutation on […]

Recent Companion Dx Deals

Companion diagnostics are rising to the forefront of pharmaceutical development and treatment. Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics can also decrease costs by identifying the patient population that will most likely benefit from the […]